BACKGROUND: It has been suggested that a new strategy for HIV prevention, 'Universal Test and Treat', whereby everyone is tested for HIV once a year and treated immediately with antiretroviral therapy (ART) if they are infected, could 'eliminate' the epidemic and reduce ART costs in the long term. METHODS: We investigated the impact of test-and-treat interventions under a variety of assumptions about the epidemic using a deterministic mathematical model. RESULTS: Our model shows that such an intervention can substantially reduce HIV transmission, but that impact depends crucially on the epidemiological context; in some situations, less aggressive interventions achieve the same results, whereas in others, the proposed intervention reduces HIV by much less. It follows that testing every year and treating immediately is not necessarily the most cost-efficient strategy. We also show that a test-and-treat intervention that does not reach full implementation or coverage could, perversely, increase long-term ART costs. CONCLUSION: Interventions that prevent new infections through ART scale-up may hold substantial promise. However, as plans move forward, careful consideration should be given to the nature of the epidemic and the potential for perverse outcomes.
BACKGROUND: It has been suggested that a new strategy for HIV prevention, 'Universal Test and Treat', whereby everyone is tested for HIV once a year and treated immediately with antiretroviral therapy (ART) if they are infected, could 'eliminate' the epidemic and reduce ART costs in the long term. METHODS: We investigated the impact of test-and-treat interventions under a variety of assumptions about the epidemic using a deterministic mathematical model. RESULTS: Our model shows that such an intervention can substantially reduce HIV transmission, but that impact depends crucially on the epidemiological context; in some situations, less aggressive interventions achieve the same results, whereas in others, the proposed intervention reduces HIV by much less. It follows that testing every year and treating immediately is not necessarily the most cost-efficient strategy. We also show that a test-and-treat intervention that does not reach full implementation or coverage could, perversely, increase long-term ART costs. CONCLUSION: Interventions that prevent new infections through ART scale-up may hold substantial promise. However, as plans move forward, careful consideration should be given to the nature of the epidemic and the potential for perverse outcomes.
Authors: Julio S G Montaner; Robert Hogg; Evan Wood; Thomas Kerr; Mark Tyndall; Adrian R Levy; P Richard Harrigan Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: T B Hallett; S Dube; I Cremin; B Lopman; A Mahomva; G Ncube; O Mugurungi; S Gregson; G P Garnett Journal: Epidemics Date: 2009-03-17 Impact factor: 4.396
Authors: Elizabeth L Corbett; Beauty Makamure; Yin Bun Cheung; Ethel Dauya; Ronnie Matambo; Tsitsi Bandason; Shungu S Munyati; Peter R Mason; Anthony E Butterworth; Richard J Hayes Journal: AIDS Date: 2007-02-19 Impact factor: 4.177
Authors: Jeffrey H Herbst; Marlene Glassman; James W Carey; Thomas M Painter; Deborah J Gelaude; Amy M Fasula; Jerris L Raiford; Arin E Freeman; Camilla Harshbarger; Abigail H Viall; David W Purcell Journal: J Acquir Immune Defic Syndr Date: 2012-04-15 Impact factor: 3.731
Authors: Jennifer N Sayles; Jacqueline Rurangirwa; Min Kim; Janni Kinsler; Rangell Oruga; Mike Janson Journal: AIDS Patient Care STDS Date: 2012-07-09 Impact factor: 5.078
Authors: Brian G Williams; Reuben Granich; Kevin M De Cock; Philippe Glaziou; Abhishek Sharma; Christopher Dye Journal: Proc Natl Acad Sci U S A Date: 2010-10-25 Impact factor: 11.205
Authors: Amin Khademi; Denis Saure; Andrew Schaefer; Kimberly Nucifora; R Scott Braithwaite; Mark S Roberts Journal: Value Health Date: 2015-11-12 Impact factor: 5.725
Authors: Joshua Kaminsky; Lindsay T Keegan; C Jessica E Metcalf; Justin Lessler Journal: Philos Trans R Soc Lond B Biol Sci Date: 2019-07-08 Impact factor: 6.237
Authors: Larry W Chang; David Serwadda; Thomas C Quinn; Maria J Wawer; Ronald H Gray; Steven J Reynolds Journal: Lancet Infect Dis Date: 2013-01 Impact factor: 25.071